Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Purchased by Broderick Brian C

Broderick Brian C boosted its holdings in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) by 6.7% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 18,001 shares of the pharmaceutical company's stock after acquiring an additional 1,127 shares during the period. Vertex Pharmaceuticals comprises 1.8% of Broderick Brian C's portfolio, making the stock its 23rd largest holding. Broderick Brian C's holdings in Vertex Pharmaceuticals were worth $8,727,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. Mascagni Wealth Management Inc. acquired a new stake in Vertex Pharmaceuticals during the fourth quarter worth about $31,000. Truvestments Capital LLC lifted its position in Vertex Pharmaceuticals by 30.3% during the fourth quarter. Truvestments Capital LLC now owns 99 shares of the pharmaceutical company's stock valued at $40,000 after buying an additional 23 shares in the last quarter. Mpwm Advisory Solutions LLC acquired a new position in Vertex Pharmaceuticals during the fourth quarter valued at approximately $40,000. Midwest Capital Advisors LLC purchased a new stake in Vertex Pharmaceuticals during the fourth quarter worth approximately $41,000. Finally, Minot DeBlois Advisors LLC acquired a new stake in shares of Vertex Pharmaceuticals in the fourth quarter worth $44,000. Hedge funds and other institutional investors own 90.96% of the company's stock.

Vertex Pharmaceuticals Trading Down 2.0%

Vertex Pharmaceuticals stock opened at $441.99 on Wednesday. The company has a 50 day moving average price of $461.30 and a 200 day moving average price of $459.86. The firm has a market capitalization of $113.50 billion, a price-to-earnings ratio of -112.75 and a beta of 0.41. Vertex Pharmaceuticals Incorporated has a 52 week low of $377.85 and a 52 week high of $519.88. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.29 and a current ratio of 2.65.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last posted its quarterly earnings results on Monday, May 5th. The pharmaceutical company reported $4.06 EPS for the quarter, missing the consensus estimate of $4.29 by ($0.23). Vertex Pharmaceuticals had a negative return on equity of 3.36% and a negative net margin of 8.91%. The company had revenue of $2.77 billion for the quarter, compared to analyst estimates of $2.85 billion. During the same quarter in the prior year, the business posted $4.76 earnings per share. The business's revenue for the quarter was up 2.6% compared to the same quarter last year. Research analysts forecast that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current year.

Analysts Set New Price Targets

VRTX has been the subject of a number of research reports. Leerink Partnrs cut shares of Vertex Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, May 6th. Needham & Company LLC reaffirmed a "hold" rating on shares of Vertex Pharmaceuticals in a research report on Tuesday, May 6th. Wall Street Zen upgraded Vertex Pharmaceuticals from a "hold" rating to a "buy" rating in a report on Tuesday, March 11th. Cantor Fitzgerald reissued an "overweight" rating and set a $535.00 price target on shares of Vertex Pharmaceuticals in a research report on Tuesday, May 6th. Finally, Scotiabank lowered their price objective on shares of Vertex Pharmaceuticals from $450.00 to $442.00 and set a "sector perform" rating for the company in a research report on Tuesday, May 6th. Fourteen equities research analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $513.32.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.